Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Amylyx Pharmaceuticals Inc shares valued at $59,429 were sold by Klee Justin B. on Sep 30 ’24. At $3.20 per share, Klee Justin B. sold 18,589 shares. The insider’s holdings dropped to 3,120,569 shares worth approximately $17.91 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Cohen Joshua B sold 18,589 shares, netting a total of over 59,414 in proceeds. Following the sale of shares at $3.20 each, the insider now holds 3,220,569 shares.
Before that, Bedrosian Camille L had sold 11,442 shares from its account. In a trade valued at $36,559, the Chief Medical Officer traded Amylyx Pharmaceuticals Inc shares for $3.20 each. Upon closing the transaction, the insider’s holdings decreased to 11,442 shares, worth approximately $0.83 million.
As published in a research note from Robert W. Baird on November 18, 2024, Amylyx Pharmaceuticals Inc [AMLX] has been rated up from a Neutral to an Outperform and the price target has been revised to $11 from $3. Analysts at BofA Securities upgraded the stock from ‘”a Neutral”‘ to ‘”a Buy”‘ outlook in a report released in late October. As of March 18, 2024, Mizuho has decreased its “Buy” rating to a “Neutral” for AMLX. Earlier on March 11, 2024, Robert W. Baird downgraded its rating. Their new recommendation was “a Neutral” for AMLX stock which previously was a “an Outperform”.
Analyzing AMLX Stock Performance
During the last five days, there has been a surge of approximately 9.75%. Over the course of the year, Amylyx Pharmaceuticals Inc shares have dropped approximately -61.01%. Shares of the company reached a 52-week high of $19.95 on 02/29/24 and a 52-week low of $1.58 on 06/17/24. A 50-day SMA is recorded $4.55, while a 200-day SMA reached $3.99. Nevertheless, trading volume fell to 0.62 million shares from 1.0 million shares the previous day.
Support And Resistance Levels for Amylyx Pharmaceuticals Inc (AMLX)
According to the 24-hour chart, there is a support level at 5.42, which, if violated, would cause prices to drop to 5.11. In the upper region, resistance lies at 5.95. The next price resistance is at 6.17. RSI (Relative Strength Index) is 57.31 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.01, which suggests the price will decrease in the coming days. Percent R is at 56.67%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
